Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.

ABSTRACT:

Background

We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment.

Methods

We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer treated in multiple regions and health systems in the United States (US). Eligible patients were diagnosed with metastatic colorectal cancer and initiated first-line chemotherapy after US Food & Drug Administration (FDA) bevacizumab approval in February 2004. First-line bevacizumab therapy was defined as receiving bevacizumab within 8 weeks of starting chemotherapy for metastatic colorectal cancer. We evaluated factors associated with first-line bevacizumab treatment using logistic regression.

Results

Among 355 patients, 31

SUBMITTER: Zafar SY 

PROVIDER: S-EPMC3174931 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature